Current Research On CBD:


1.)  Xiong W, Cui T, Cheng K, et al. Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors. The Journal of Experimental Medicine. 2012;209(6):1121-1134. doi:10.1084/jem.20120242.

Acute & Chronic Pain

2.) Neelakantan, H., Tallarida, R.J., Reichenbach, Z.W., Tuma, R.F., Ward, S.J. and Walker, E.A., 2015. Distinct interactions of cannabidiol and morphine in three nociceptive behavioral models in mice. Behavioural pharmacology, 26(3), pp.304-314.Schizophrenia Research. 162 (1–3): 153–61.


3.) Fitzcharles, M. A., Baerwald, C., Ablin, J., & Häuser, W. (2016). Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis). Der Schmerz30(1), 47-61.


4.) Antonio Waldo Zuardi, Jose Alexandre S. Crippa, Jaime E.C. Hallak, Sagnik Bhattacharyya, Zerrin Atakan, Rocio Martin-Santos, Philip K. McGuire and Francisco Silveira Guimaraes. Current Pharmaceutical Design (2012) 18: 5131. Schizophrenia Research. 162 (1–3): 153–61.


5.) Zanelati TV, Biojone C, Moreira FA, Guimarães FS, Joca SR (January 2010). “Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors”. British Journal of Pharmacology. 159 (1): 122–8. doi:10.1111/j.1476-5381.2009.00521.x.Schizophrenia Research. 162 (1–3): 153–61.


6.) Hurd YL, Yoon M, Manini AF, et al. Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage. Neurotherapeutics. 2015;12(4):807-815. doi:10.1007/s13311-015-0373-7.Schizophrenia Research. 162 (1–3): 153–61.


7.) Lehmann, C., Fisher, N.B., Tugwell, B., Szczesniak, A., Kelly, M. and Zhou, J., 2016. Experimental cannabidiol treatment reduces early pancreatic inflammation in type 1 diabetes. Clinical hemorheology and microcirculation, 64(4), pp.655-662.Schizophrenia Research. 162 (1–3): 153–61.

Anxiety Disorders (PTSD & Social Anxiety)

8.) Bergamaschi MM, Queiroz RHC, Chagas MHN, et al. Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients. Neuropsychopharmacology. 2011;36(6):1219-1226. doi:10.1038/npp.2011.6.

Sleep Disorders

9.) Babson, K. A., Sottile, J., & Morabito, D. (2017). Cannabis, cannabinoids, and sleep: a review of the literature. Current psychiatry reports19(4), 23.

Non-psychoactiveness of CBD

Iseger TA, Bossong MG (March 2015). “A systematic review of the antipsychotic properties of cannabidiol in humans”. Schizophrenia Research. 162 (1–3): 153–61.

Neuroprotective Effects

Mishima K, Hayakawa K, Abe K, Ikeda T, Egashira N, Iwasaki K, Fujiwara M (May 2005). “Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism”. Stroke. 36 (5): 1077–82. doi:10.1161/01.STR.0000163083.59201.34 Schizophrenia Research. 162 (1–3): 153–61.

Hayakawa K, Mishima K, Nozako M, Ogata A, Hazekawa M, Liu AX, Fujioka M, Abe K, Hasebe N, Egashira N, Iwasaki K, Fujiwara M (March 2007). “Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance”. Neuropharmacology. 52 (4): 1079–87. doi:10.1016/j.neuropharm.2006.11.005 Schizophrenia Research. 162 (1–3): 153–61.

Antioxidant Effect

Campos AC, Guimarães FS (August 2008). “Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats”. Psychopharmacology. 199 (2): 223–30. doi:10.1007/s00213-008-1168-x.Schizophrenia Research. 162 (1–3): 153–61.


Scotter, E. L., Abood, M. E. and Glass, M. (2010), The endocannabinoid system as a target for the treatment of neurodegenerative disease. British Journal of Pharmacology, 160: 480-498. doi:10.1111/j.1476-5381.2010.00735.xSchizophrenia Research. 162 (1–3): 153–61.

Esposito, G., De Filippis, D., Carnuccio, R. et al. J Mol Med (2006) 84: 253. Research. 162 (1–3): 153–61.

Multiple Sclerosis

Giacoppo, S., Pollastro, F., Grassi, G., Bramanti, P. and Mazzon, E., 2017. Target regulation of PI3K/Akt/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis. Fitoterapia, 116, pp.77-84 Schizophrenia Research. 162 (1–3): 153–61.


Guindon, J. and Hohmann, A. G. (2011), The endocannabinoid system and cancer: therapeutic implication. British Journal of Pharmacology, 163: 1447-1463. doi:10.1111/j.1476-5381.2011.01327.xSchizophrenia Research. 162 (1–3): 153–61.

McAllister SD, Soroceanu L, Desprez P-Y. The antitumor activity of plant-derived non-psychoactive cannabinoids. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 2015;10(2):255-267. doi:10.1007/s11481-015-9608-y.Schizophrenia Research. 162 (1–3): 153–61.